Avacincaptad pegol

Drug Profile

Avacincaptad pegol

Alternative Names: Anti-C5 aptamer; ARC-187; ARC-1905; Avacincaptad pegol sodium; Zimura

Latest Information Update: 19 Apr 2017

Price : $50

At a glance

  • Originator Archemix Corporation
  • Developer OphthoTech Corporation
  • Class Eye disorder therapies; Oligonucleotides; Polyethylene glycols
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Dry age-related macular degeneration
  • Phase II Wet age-related macular degeneration

Most Recent Events

  • 28 Feb 2017 Ophthotech has patents pending for avacincaptad pegol in USA, European union, Japan and other jurisdictions (Ophthotech form 10-k, February 2017)
  • 27 Jan 2016 Ophthotech Corporation initiates enrolment in a phase II clinical trials in Wet age-related macular degeneration (Combination therapy) in USA (Intravitreous)
  • 27 Jan 2016 Phase-II/III clinical trials in Dry age-related macular degeneration in USA (Intravitreous) (NCT02686658)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top